生殖系
生物
遗传学
基因检测
海绵状畸形
拷贝数变化
体细胞
外显子
基因
病理
基因组
医学
病变
作者
Neblina Sikta,Samuel Gooley,Timothy E. Green,Olivia Hoeper,Tom Witkowski,Caitlin A. Bennett,David Francis,Joshua Reid,Kevin Mao,Mohammed Awad,Samuel Roberts-Thomson,Kristian J. Bulluss,Jonathan R. Clark,Ingrid E. Scheffer,Piero Perucca,Mark F. Bennett,Melanie Bahlo,Samuel F. Berkovic,Michael S. Hildebrand
摘要
Abstract Cerebral cavernous malformations (CCMs) are intracranial vascular lesions associated with risk of haemorrhages and seizures. While the majority are sporadic and often associated with somatic variants in PIK3CA and MAP3K3, around 20% are familial with germline variants in one of three CCM genes—KRIT1/CCM1, CCM2 and PDCD10/CCM3. We performed comprehensive phenotyping and genetic analysis of nine multiplex families and ten sporadic individuals with CCM. In the familial cases, initial standard analyses had a low yield, we therefore searched for small copy number changes and deep intronic variants. Subsequently, pathogenic germline variants in KRIT1/CCM1 or CCM2 were identified in all 9 multiplex families. Single or multiple exon deletions or splice site variants in KRIT1/CCM1 were found in 3/9 families. Where cavernous malformation tissue was available, second hit somatic PIK3CA variants were identified in 4/7 individuals. These 4 individuals were from separate families with germline KRIT1/CCM1 variants. In 8/10 sporadic cases, we detected recurrent pathogenic somatic PIK3CA, MAP3K3 or CCM2 variants. All familial cases had multiple CCMs, whereas the sporadic cases had a single lesion only, which was in the temporal lobe in 9/10 individuals. Our comprehensive approach interrogating deep intronic variants combined with detection of small copy number variants warrants implementation in standard clinical genetic testing pipelines to increase diagnostic yield. We also build on the established second hit germline and somatic variant mechanism in some CCM lesions. Genetic diagnosis has clinical implications such as reproductive counselling and provides potential eligibility for precision medicine therapies to treat rapidly growing CCMs.
科研通智能强力驱动
Strongly Powered by AbleSci AI